Aaron J Osborne

US Patent:

20210100856, Apr 8, 2021

Filed:

Sep 10, 2020

Appl. No.:

17/017469

Inventors:

- Redwood City CA, US
Szilard KISS - New York NY, US
Aaron OSBORNE - San Mateo CA, US
Adam TURPCU - Oakland CA, US

International Classification:

A61K 35/761
A61K 9/00
A61P 27/02
A61K 38/16

Abstract:

Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide comprising an amino acid sequence with at least about 95% identity to the amino acid sequence of SEQ ID NO: 35 and flanked by AAV2 inverted terminal repeats (ITRs), and b) an AAV2 capsid protein comprising an amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to an AAV2 VP1 capsid protein.